Former Lumiata COO leads pharma-backed investment firm targeting digital health startups

The convergence between digital health and pharmaceutical companies has been an interesting trend to witness in the past few years. Increasingly, pharma companies want to move from being customers of digital health companies to having a role in steering their future as investors. So it shouldn’t be surprising that drug developers based in Japan — the second largest market for pharmaceuticals — are also getting involved. Tokyo-based Astellas Pharma has partnered with early stage life sciences venture investing firm MPM Capital to launch DigiTx Partners in San Francisco.